GlassScriptPhysician profile
Krystal Smith
NPI 1992331573
$4,719.55
in general payments reported to CMS, 2019-2025
21 companies · $711 in 2025
The $711 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $610 · 2022: $1,005 · 2023: $1,320 · 2024: $1,074 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,104.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $982.75 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $853.98 | 2021-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $511.06 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $459.47 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $308.64 | 2021-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $269.57 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $221.31 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $196.87 | 2022-2025 | Auvelity |
| Alkermes, INC. | $193.26 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $130.09 | 2022-2025 | Fanapt |
| Corium, LLC | $126.71 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $107.07 | 2024-2025 | Ingrezza |
| Neos Therapeutics, LP | $97.37 | 2021-2023 | Adzenys Xr-Odt |
| Indivior INC. | $81.67 | 2023-2024 | Sublocade |
| Bausch Health US, LLC | $41.10 | 2022-2023 | Wellbutrin, Aplenzin |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $35.65 | 2022-2023 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $30.76 | 2025 | Cobenfy |
| Tris Pharma INC | $22.68 | 2023 | Dyanavel Xr |
| Almatica Pharma LLC | $20.50 | 2022 | |
| Eisai INC. | $15.09 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.95 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystal Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.